Eugene A. Woltering

TL;DR: This consensus report gives a detailed description of the use of somatostatin analogs in the management of neuroendocrine tumors of the gastroenteropancreatic system and defines the binding affinities of different somatosteroid analogs to the five different subtypes of som atostatin receptor.

TL;DR: Well-differentiated neuroendocrine tumors (NETs) of the jejunum, ileum, and appendix are also collectively known as midgut carcinoids and have substantial risk of relapse after resection and need to be followed for at least 7 years.

TL;DR: This clinical trial was performed to determine the effectiveness and tolerability of therapeutic doses of (111)In-pentetreotide in patients with GEP tumors and found that two doses are safe, well-tolerated, and improve symptoms in 62% of patients, decrease hormonal markers in 81% of customers, decrease Hounsfield units on computed tomography (CT) scans in 27% of Patients, with 8% partial radiographic responses and increased expected survival in GEP cancer patients

TL;DR: The natural history of this disease is invariably attended by a long history of vague abdominal symptoms, a series of visits to a primary care practitioner, and referral to a gastroenterologist, often with a misdiagnosis of IBS, so a greater index of suspicion and a carcinoid tumor profile screen are warranted.

TL;DR: Final treatment recommendations for patients with either bronchial or thymic neuroendocrine NETs of the thorax should be individualized, weighing the risks and benefits of therapy.